Special Analysis: Two Key Legislative Initiatives Labs Should Know About
Though potential FDA LDTs regulation has drawn a lot of attention, other efforts could also have long-term effects on how labs do business.
Author Information
Scott Wallask
Posts by the Author
Special Report: Will the COVID-19 Recovery Be Bumpier than Expected?
Though IVD and commercial lab Q3 2023 earnings reports held promising signs, Q4 2024 and FY2023 results tell a different story.
The Benefits of Penetration Tests in Labs
Cybersecurity expert explains the importance of such assessments, which simulate malicious attacks to identify IT vulnerabilities.
Quick Guide to Recent Changes We’ve Made to G2’s Reports
A new name comes with Lab Industry Advisor, but the goal of helping labs remains the same.
Compliance Tool: 8 Questions to Ask About Digital Pathology Business Arrangements
This checklist can help labs monitor their organization’s business arrangements that concern digital pathology to ensure compliance.
Digital Pathology Business Arrangements Bring Fraud and Kickback Worries
Healthcare attorneys explain three digital pathology models for laboratories to be aware of.
OSHA Citations for Hazardous Chemicals in Labs May Stem from Subpar Training
Standard 1910.1450 requires labs to have a chemical hygiene plan.
FDA’s LDT Proposal Raises Questions About Clinical Validity
Debate is underway on whether current CLIA review of LDTs properly assesses a test’s likelihood to detect diseases.
